Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors von Das, Satya, Johnson, Douglas B.

Volltext

Immune-checkpoint inhibitors: long-term implications of toxicity von Johnson, Douglas B., Nebhan, Caroline A., Moslehi, Javid J., Balko, Justin M.

Volltext

Endocrine toxicities of immune checkpoint inhibitors von Wright, Jordan J., Powers, Alvin C., Johnson, Douglas B.

Volltext

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis von Moslehi, Javid J, Salem, Joe-Elie, Sosman, Jeffrey A, Lebrun-Vignes, Bénédicte, Johnson, Douglas B

Volltext

Immune checkpoint inhibitors in challenging populations von Johnson, Douglas B., Sullivan, Ryan J., Menzies, Alexander M.

Volltext

Biological Consequences of MHC-II Expression by Tumor Cells in Cancer von Axelrod, Margaret L, Cook, Rebecca S, Johnson, Douglas B, Balko, Justin M

Volltext

Corticosteroids and Cancer Immunotherapy von Goodman, Rachel S, Johnson, Douglas B, Balko, Justin M

Volltext

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance von Hugo, Willy, Shi, Hubing, Sun, Lu, Piva, Marco, Song, Chunying, Kong, Xiangju, Moriceau, Gatien, Hong, Aayoung, Dahlman, Kimberly B., Johnson, Douglas B., Sosman, Jeffrey A., Ribas, Antoni, Lo, Roger S.

Volltext

Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy von Shae, Daniel, Becker, Kyle W., Christov, Plamen, Yun, Dong Soo, Lytton-Jean, Abigail K. R., Sevimli, Sema, Ascano, Manuel, Kelley, Mark, Johnson, Douglas B., Balko, Justin M., Wilson, John T.

Volltext

Melanoma: What do all the mutations mean? von Davis, Elizabeth J., Johnson, Douglas B., Sosman, Jeffrey A., Chandra, Sunandana

Volltext

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma von Hugo, Willy, Zaretsky, Jesse M., Sun, Lu, Song, Chunying, Moreno, Blanca Homet, Hu-Lieskovan, Siwen, Berent-Maoz, Beata, Pang, Jia, Chmielowski, Bartosz, Cherry, Grace, Seja, Elizabeth, Lomeli, Shirley, Kong, Xiangju, Kelley, Mark C., Sosman, Jeffrey A., Johnson, Douglas B., Ribas, Antoni, Lo, Roger S.

Volltext

Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction von Moriceau, Gatien, Hugo, Willy, Hong, Aayoung, Shi, Hubing, Kong, Xiangju, Yu, Clarissa C., Koya, Richard C., Samatar, Ahmed A., Khanlou, Negar, Braun, Jonathan, Ruchalski, Kathleen, Seifert, Heike, Larkin, James, Dahlman, Kimberly B., Johnson, Douglas B., Algazi, Alain, Sosman, Jeffrey A., Ribas, Antoni, Lo, Roger S.

Volltext

A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention von Wei, Spencer C, Meijers, Wouter C, Axelrod, Margaret L, Anang, Nana-Ama A S, Screever, Elles M, Wescott, Elizabeth C, Johnson, Douglas B, Whitley, Elizabeth, Lehmann, Lorenz, Courand, Pierre-Yves, Mancuso, James J, Himmel, Lauren E, Lebrun-Vignes, Benedicte, Wleklinski, Matthew J, Knollmann, Bjorn C, Srinivasan, Jayashree, Li, Yu, Atolagbe, Oluwatomisin T, Rao, Xiayu, Zhao, Yang, Wang, Jing, Ehrlich, Lauren I R, Sharma, Padmanee, Salem, Joe-Elie, Balko, Justin M, Moslehi, Javid J, Allison, James P

Volltext

Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis von Wang, Daniel Y., Ye, Fei, Zhao, Shilin, Johnson, Douglas B.

Volltext

Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study von Cortazar, Frank B, Kibbelaar, Zoe A, Glezerman, Ilya G, Abudayyeh, Ala, Mamlouk, Omar, Motwani, Shveta S, Murakami, Naoka, Herrmann, Sandra M, Manohar, Sandhya, Shirali, Anushree C, Kitchlu, Abhijat, Shirazian, Shayan, Assal, Amer, Vijayan, Anitha, Renaghan, Amanda DeMauro, Ortiz-Melo, David I, Rangarajan, Sunil, Malik, A Bilal, Hogan, Jonathan J, Dinh, Alex R, Shin, Daniel Sanghoon, Marrone, Kristen A, Mithani, Zain, Johnson, Douglas B, Hosseini, Afrooz, Uprety, Deekchha, Sharma, Shreyak, Gupta, Shruti, Reynolds, Kerry L, Sise, Meghan E, Leaf, David E

Volltext

Immune Checkpoint Inhibitor‐Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis von Grouthier, Virginie, Lebrun‐Vignes, Bénédicte, Moey, Melissa, Johnson, Douglas B., Moslehi, Javid J., Salem, Joe‐Elie, Bachelot, Anne

Volltext

Combinatorial approach to cancer immunotherapy: strength in numbers von Vilgelm, Anna E., Johnson, Douglas B., Richmond, Ann

Volltext

Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes von Wright, Jordan J, Salem, Joe-Elie, Johnson, Douglas B, Lebrun-Vignes, Bénédicte, Stamatouli, Angeliki, Thomas, James W, Herold, Kevan C, Moslehi, Javid, Powers, Alvin C

Volltext

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy von Johnson, Douglas B., Estrada, Monica V., Salgado, Roberto, Sanchez, Violeta, Doxie, Deon B., Opalenik, Susan R., Vilgelm, Anna E., Feld, Emily, Johnson, Adam S., Greenplate, Allison R., Sanders, Melinda E., Lovly, Christine M., Frederick, Dennie T., Kelley, Mark C., Richmond, Ann, Irish, Jonathan M., Shyr, Yu, Sullivan, Ryan J., Puzanov, Igor, Sosman, Jeffrey A., Balko, Justin M.

Volltext

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma von Hugo, Willy, Zaretsky, Jesse M., Sun, Lu, Song, Chunying, Moreno, Blanca Homet, Hu-Lieskovan, Siwen, Berent-Maoz, Beata, Pang, Jia, Chmielowski, Bartosz, Cherry, Grace, Seja, Elizabeth, Lomeli, Shirley, Kong, Xiangju, Kelley, Mark C., Sosman, Jeffrey A., Johnson, Douglas B., Ribas, Antoni, Lo, Roger S.

Volltext